Inovio, Coherus Biosciences announces clinical collaboration

Inovio (INO) announced a clinical collaboration and supply agreement with Coherus BioSciences (CHRS) to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma, a type of head and neck cancer commonly known as throat cancer. Under the terms of the supply agreement, Coherus will provide LOQTORZI for a Phase 3 clinical trial to be conducted by Inovio, pending alignment with the U.S. FDA on study design. LOQTORZI is a PD-1 inhibitor recently approved by the FDA for the treatment of recurrent locally advanced/metastatic nasopharyngeal carcinoma.